Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
Michelle A. Rudek(Dana-Farber Cancer Institute), Antonio C. Wolff(Johns Hopkins University), John H. Fetting(Johns Hopkins University), Ming Zhao(Sidney Kimmel Comprehensive Cancer Center), Elizabeth Garrett‐Mayer(Novartis (Switzerland)), Laurie A. Wright(Johns Hopkins University), Nancy E. Davidson(WinnMed), Vered Stearns(Johns Hopkins University), Deborah K. Armstrong(Johns Hopkins University), Stanley P. Watkins(Anne Arundel Medical Center), Stacie C. Jeter(Johns Hopkins University), Roisín M. Connolly(Johns Hopkins University), Janelle M. Hoskins(University of North Carolina at Chapel Hill), Howard L. McLeod(Unknown)
Cited by 17
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)
|Archives of Pathology & Laboratory Medicine|2010|1.1k